Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PN-951
- Development stage
- Discontinued
- Lead developer
- Wellstat Therapeutics
- Modality
- Small Molecules
01
Overview
PN-951 is a discontinued small molecule uridine prodrug developed by Wellstat Therapeutics (formerly Pro-Neuron) for the treatment of hematologic diseases, specifically chemotherapy-induced myelosuppression. The compound was designed to increase systemic levels of uridine, a key pyrimidine nucleoside essential for the synthesis of RNA and DNA in rapidly dividing cells. By augmenting the pyrimidine salvage pathway, PN-951 aimed to protect hematopoietic stem cells and accelerate the recovery of blood cell counts, such as neutrophils and platelets, following damage from cytotoxic chemotherapeutic agents. Clinical development of PN-951 reached Phase 1 trials before the program was discontinued.
Beyond the preview
Go deeper on PN-951.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PN-951.